These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33809005)

  • 1. Expression of Phosphorylated BRD4 Is Markedly Associated with the Activation Status of the PP2A Pathway and Shows a Strong Prognostic Value in Triple Negative Breast Cancer Patients.
    Sanz-Álvarez M; Cristóbal I; Luque M; Santos A; Zazo S; Madoz-Gúrpide J; Caramés C; Chiang CM; García-Foncillas J; Eroles P; Albanell J; Rojo F
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33809005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
    Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
    Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumoral BRD4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival.
    Lee M; Tayyari F; Pinnaduwage D; Bayani J; Bartlett JMS; Mulligan AM; Bull SB; Andrulis IL
    BMC Cancer; 2018 Jul; 18(1):750. PubMed ID: 30029633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
    Mio C; Gerratana L; Bolis M; Caponnetto F; Zanello A; Barbina M; Di Loreto C; Garattini E; Damante G; Puglisi F
    Int J Cancer; 2019 Feb; 144(4):755-766. PubMed ID: 30259975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
    Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
    EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and biological evaluation of quinazolin-4(3
    Chang X; Sun D; Shi D; Wang G; Chen Y; Zhang K; Tan H; Liu J; Liu B; Ouyang L
    Acta Pharm Sin B; 2021 Jan; 11(1):156-180. PubMed ID: 33532187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PP2A as the Main Node of Therapeutic Strategies and Resistance Reversal in Triple-Negative Breast Cancer.
    Zhao H; Li D; Zhang B; Qi Y; Diao Y; Zhen Y; Shu X
    Molecules; 2017 Dec; 22(12):. PubMed ID: 29261144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of BRD4 phosphorylation in the nucleus accumbens in relapse to cocaine-seeking behavior in mice.
    Guo W; Long H; Bu Q; Zhao Y; Wang H; Tian J; Cen X
    Addict Biol; 2020 Sep; 25(5):e12808. PubMed ID: 31364211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells.
    Gayle SS; Sahni JM; Webb BM; Weber-Bonk KL; Shively MS; Spina R; Bar EE; Summers MK; Keri RA
    J Biol Chem; 2019 Jan; 294(3):875-886. PubMed ID: 30482844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bromodomain 4 is a potent prognostic marker associated with immune cell infiltration in breast cancer.
    Zhong L; Yang Z; Lei D; Li L; Song S; Cao D; Liu Y
    Basic Clin Pharmacol Toxicol; 2021 Jan; 128(1):169-182. PubMed ID: 32799413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects.
    Rincón R; Cristóbal I; Zazo S; Arpí O; Menéndez S; Manso R; Lluch A; Eroles P; Rovira A; Albanell J; García-Foncillas J; Madoz-Gúrpide J; Rojo F
    Oncotarget; 2015 Feb; 6(6):4299-314. PubMed ID: 25726524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Prognostic Role of BRD4 Expression in High-Grade Serous Ovarian Cancer.
    Andrikopoulou A; Bletsa G; Rouvalis A; Tsakogiannis D; Kaparelou M; Papatheodoridi A; Haidopoulos D; Liontos M; Dimopoulos MA; Zagouri F
    Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases.
    Sahni JM; Gayle SS; Bonk KL; Vite LC; Yori JL; Webb B; Ramos EK; Seachrist DD; Landis MD; Chang JC; Bradner JE; Keri RA
    J Biol Chem; 2016 Nov; 291(45):23756-23768. PubMed ID: 27650498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
    Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
    Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer.
    Park IH; Yang HN; Jeon SY; Hwang JA; Kim MK; Kong SY; Shim SH; Lee KS
    Sci Rep; 2019 Sep; 9(1):13305. PubMed ID: 31527644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S100A14 is a novel independent prognostic biomarker in the triple-negative breast cancer subtype.
    Ehmsen S; Hansen LT; Bak M; Brasch-Andersen C; Ditzel HJ; Leth-Larsen R
    Int J Cancer; 2015 Nov; 137(9):2093-103. PubMed ID: 25912829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the Heterogeneous Genomic Landscape in Triple-Negative Breast Cancer through Inhibitors of the Transcriptional Machinery.
    van der Noord VE; van de Water B; Le Dévédec SE
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macrophages confer resistance to BET inhibition in triple-negative breast cancer by upregulating IKBKE.
    Qiao J; Chen Y; Mi Y; Jin H; Wang L; Huang T; Li H; Song Y; Cao J; Wu B; Wang Q; Zou Z
    Biochem Pharmacol; 2020 Oct; 180():114126. PubMed ID: 32603665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
    Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
    PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nectin-4 Expression Is an Independent Prognostic Biomarker and Associated With Better Survival in Triple-Negative Breast Cancer.
    Zeindler J; Soysal SD; Piscuoglio S; Ng CKY; Mechera R; Isaak A; Weber WP; Muenst S; Kurzeder C
    Front Med (Lausanne); 2019; 6():200. PubMed ID: 31572728
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.